Prevailing genotypes of hepatitis C virus in Saudi Arabia: A systematic analysis of evidence

Annals of Saudi Medicine

Volumn 33, Issue 1, 2013, Pages 1-5

  Abozaid, Suhair M ^a   Shoukri, Mohamed ^a,b   Al Qahtani, Ahmad ^a,c   Al Ahdala, Mohammed N ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b WESTERN UNIVERSITY   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SAUDI ARABIA; SYSTEMATIC REVIEW; VIRUS STRAIN;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PREVALENCE; SAUDI ARABIA;

EID: 84873906206     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2013.1     Document Type: Review

References (33)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74-81.
2. Hoofnagle JH. Natural history of hepatitis C. Hepatology 1997;26(Suppl 1): S21-8.
3. Seeff LB. Natural history of hepatitis C. Hepatology 2002;36(Suppl 1):S35-S46.
4. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol 2007;42:411-23.
5. Smith DB, Simmonds P. Hepatitis C Virus: Types, Subtypes, and Beyond. Methods Mol Med 2008;19:133-46.
6. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996;23:695-9.
7. Yu M-L, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol 2009;24:336-45.
8. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-125.
9. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HC V genotypes. Antivir Ther 2005;10:1-11.
10. Al-Qahtani AA, Kessie G, Dela Cruz D, Al-Faleh FZ, Al-Ahdal MN. Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alpha and ribavirin therapy. Ann Saudi Med 2010;30:109-14.
11. Aurora R, Donlin MJ, Cannon NA, Tavis JE. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009;119:225-36.
12. al-Faleh FZ, Huraib S, Sbeih F, al-Karawi M, al-Rashed R, al-Mofleh IA, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J. Viral Hepat 1995;2:293-6.
13. Al-Ahdal MN, Rezeig MA, Kessie G. Genotyping of hepatitis C virus isolates from Saudi patients by analysis of sequences from PCR -amplified core region of the virus genome. Ann Saudi Med 1997;17:601-4.
14. Fakeeh M, Zaki AM. Hepatitis C: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. Am J Trop Med Hyg 1999;61:889-92.
15. Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999;58:44-8.
16. Boriskin YS, Bakir TM, al-Aska AI, Booth JC. Is hepatitis C virus genotype 4 predominant in Saudi Arabia? New Microbiol 1999;22:173-80.
17. Al-Faleh FZ, Aljumah A, Rezeig M, Al-Kanawi, Al-Otaibi M, Alahdal M, et al. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 2000;7:287-91.
18. Osoba AO, Ibrahim M, Abdelaal MA, Al-Mowallad A, Al Shareef B, Hussein BA. Hepatitis C virus genotyping by polymerase chain reaction and DN A enzyme immunoassay among Saudi patients in the Western Province, Saudi Arabia. Ann Saudi Med 2000;20:394-7.
19. Akbar HO. Effect of induction therapy on Hepatitis C. Saudi Med J 2002;23:773-6.
20. Al-Knawy B, Okamoto H, Ahmed El-Mekki A, Elbagir Khalafalla M, Al Wabel A, Qazi F, et al. Distribution of hepatitis C genotype and co-infection rate with hepatitis G in Saudi Arabia. Hepatol Res 2002;24:95-8.
21. Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Med J 2003;24(Suppl 2):S87-S91.
22. Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004;25:1935-8.
23. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Alghamedi A, Alashgar H, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568- 74.
24. Al Ashgar H, Khan MQ, Helmy A, Al Swat K, Al Shehri A, Al Kalbani A, et al. Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience. Saudi J Gastroenterol 2008;14:58-65.
25. Dahlan Y, Ather HM, Al-Ahmadi M, Batwa F, Al-Hamoudi W. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. World J. Gastroenterol 2009;15:4429-33.
26. Alzahrani AJ, Dela Cruz DM, Obeid OE, Bukhari HA, Al-Qahtani AA, Al-Ahdal MN. Molecular detection of hepatitis B, hepatitis C, and torque teno viruses in drug users in Saudi Arabia. J Med Virol 2009;81:1343-7.
27. Mudawi H, Helmy A, Kamel Y, Al Saghier M, Al Sofayan M, Al Sebayel M, et al. Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: natural history and predictors of outcome. Ann Saudi Med 2009;29:91-7.
28. Issa H. Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. World J Hepatol 2010;2:180-4.
29. Alqaraawi AM, Sanai FM, Al-Husseini H, Albenmousa A, AlSheikh A, Ahmed LR, et al. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C. Dig Dis Sci 2011;56:1222-8.
30. Sidik K, Jonkman JN. A note on variance estimation in random effects meta-regression. J Biopharm Stat 2005;15:823-38.
31. Al-Faleh FZ, Ramia S. Hepatitis C virus (HC V) infection in Saudi Arabia. Ann Saudi Med 1997;17:77-82.
32. Le Guillou-Guillemette HL, Vallet S, Gaudy- Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. World J Gastroenterol 2007;13:2416-26.
33. Zein NN . Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-235.